ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRMD vs PRCT // EV/EBITDA & P/E VALUATION

iRadimed Corporation (NASDAQ) VS. PROCEPT BioRobotics Corporation (NASDAQ) • 15-METRIC TALLY: IRMD 7 — PRCT 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRMD VS. PRCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRMD PRCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 76.70% 63.70% +13.00 IRMD /gross-margins <GO>
Return on Invested Capital (ROIC) 37.70% -35.00% +72.70 IRMD /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 31.9x — — TIE /valuation <GO>
Free Cash Flow Yield 1.57% -5.02% +6.59 IRMD /fcf-yield <GO>
Operating Margin 31.20% -33.70% +64.90 IRMD /operating-margins <GO>
Net Profit Margin 26.80% 0.00% +26.80 IRMD /net-margins <GO>
Revenue Growth (YoY) 14.40% 37.20% -22.80 PRCT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 1.37% 0.00% +1.37 IRMD /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.98 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 8/9 4/9 +4.00 IRMD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 25.6 50.7 -25.08 PRCT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 41.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.10B $1.16B -$66.3M PRCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRMD REV PRCT REV IRMD GROSS % PRCT GROSS % IRMD FCF PRCT FCF
FY 2025 $83.8M $308.1M 76.7% 63.7% $17.2M -$58.3M
FY 2024 $73.2M $224.5M 76.9% 61.1% $17.6M -$103.6M
FY 2023 $65.6M $136.2M — — $13.5M -$108.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRMD // BETA —
PRCT // BETA —